Janus kinase 3-activating mutations identifi ed in natural killer/T-cell lymphoma

Cancer Discovery

Volumn 2, Issue 7, 2012, Pages 591-597

  Koo, Ghee Chong ^a   Tan, Soo Yong ^b,d   Tang, Tiffany ^a   Poon, Song Ling ^a   Allen, George E ^a   Tan, Leonard ^b   Chong, Soo Ching ^a   Ong, Whee Sze ^a   Tay, Kevin ^a   Tao, Miriam ^a   Quek, Richard ^a   Loong, Susan ^a   Yeoh, Kheng Wei ^a   Yap, Swee Peng ^a   Lee, Kuo Ann ^a   Lim, Lay Cheng ^b   Tan, Daryl ^b   Goh, Christopher ^b   Cutcutache, Ioana ^c   Yu, Willie ^a   Ng, Cedric Chuan Young ^a   Rajasegaran, Vikneswari ^a   Heng, Hong Lee ^a   Gan, Anna ^a   Ong, Choon Kiat ^a   Rozen, Steve ^c   Tan, Patrick ^e,f   Teh, Bin Tean ^a   Lim, Soon Thye ^a,d   more..

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 2; JANUS KINASE 3; STAT PROTEIN; STAT5 PROTEIN; TOFACITINIB;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; EPSTEIN BARR VIRUS; EXOME; FLOW CYTOMETRY; GENE MUTATION; GENE SEQUENCE; GENETIC TRANSFECTION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NK T CELL LYMPHOMA; SOMATIC MUTATION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DNA MUTATIONAL ANALYSIS; ENZYME ACTIVATION; FEMALE; HUMANS; JANUS KINASE 3; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; MUTATION; NATURAL KILLER T-CELLS; PHOSPHORYLATION; PYRIMIDINES; PYRROLES; RNA INTERFERENCE; STAT5 TRANSCRIPTION FACTOR;

EID: 84866314162     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0028     Document Type: Article

References (28)

1. Kwong YL, Anderson BO, Advani R, Kim WS, Levine AM, Lim ST. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009;10:1093-101.
2. Au WY, Ma SY, Chim CS, Choy C, Loong F, Lie AK, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 2005;16:206-14.
3. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killeraT-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-30.
4. Takahara M, Kishibe K, Bandoh N, Nonaka S, Harabuchi Y. P53, Nand K-Ras, and beta-catenin gene mutations and prognostic factors in nasal NKiT-cell lymphoma from Hokkaido, Japan. Hum Pathol 2004;35:86-95.
5. Sunyaev S, Ramensky V, Koch I, Lathe W III, Kondrashov AS, Bork P. Prediction of deleterious human alleles. Hum Mol Genet 2001;10: 591-7.
6. Suzuki R, Handa K, Itoh K, Kumagai K. Natural killer (NK) cells as a responder to interleukin 2 (IL 2). I. Proliferative response and establishment of cloned cells. J Immunol 1983;130:981-7.
7. Lu L, Zhu J, Zheng Z, Yan M, Xu W, Sun L, et al. Jak-STAT pathway is involved in the induction of TNF-beta gene during stimulation by IL-2. Eur J Immunol 1998;28:805-10.
8. Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006;10:65-75.
9. Notarangelo LD, Mella P, Jones A, de Saint Basile G, Savoldi G, Cranston T, et al. Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency. Hum Mutat 2001;18:255-63.
10. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008;205:751-8.
11. Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008;372:1484-92.
12. Elliott NE, Cleveland SM, Grann V, Janik J, Waldmann TA, Dave UP. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemiaTlymphoma. Blood 2011;118:3911-21.
13. Krejsgaard T, Vetter-Kauczok CS, Woetmann A, Lovato P, Labuda T, Eriksen KW, et al. Jak3-and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 2006;20:1759-66.
14. Yared MA, Khoury JD, Medeiros LJ, Rassidakis GZ, Lai R. Activation status of the JAKsSTAT3 pathway in mantle cell lymphoma. Arch Pathol Lab Med 2005;129:990-6.
15. Kiyoi H, Yamaji S, Kojima S, Naoe T. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia 2007;21:574-6.
16. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
17. Jeong EG, Kim MS, Nam HK, Min CK, Lee S, Chung YJ, et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res 2008;14:3716-21.
18. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75.
19. Malinge S, Ragu C, Della-Valle V, Pisani D, Constantinescu SN, Perez C, et al. Activating mutations in human acute megakaryoblastic leukemia. Blood 2008;112:4220-6.
20. Yamashita Y, Yuan J, Suetake I, Suzuki H, Ishikawa Y, Choi YL, et al. Array-based genomic resequencing of human leukemia. Oncogene 2010;29:3723-31.
21. Cornejo MG, Kharas MG, Werneck MB, Le Bras S, Moore SA, Ball B, et al. Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood 2009;113:2746-54.
22. Manshouri T, Quintas-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, et al. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci 2008;99:1265-73.
23. Ju W, Zhang M, Jiang JK, Thomas CJ, Oh U, Bryant BR, et al. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAMHTSP. Blood 2011;117:1938-46.
24. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2008;117: 5019-32.
25. Marchetti A, Felicioni L, Buttitta F. Assessing EGFR mutations. N Engl J Med 2006;354:526-8; author reply 526-8.
26. Solassol J, Ramos J, Crapez E, Saifi M, Mange A, Vianes E, et al. KRAS mutation detection in paired frozen and formalin-fixed paraffin-embedded (FFPE) colorectal cancer tissues. Int J Mol Sci 2011; 12:3191-204.
27. Loong SL, Hwang JS, Lim ST, Yap SP, Tao M, Chong TW, et al. An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing. Leuk Lymphoma 2008;49:1161-7.
28. Yagita M, Huang CL, Umehara H, Matsuo Y, Tabata R, Miyake M, et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 2000;14:922-30.